Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploring Kidney Oxygenation Responses to Dapagliflozin, Exenatide, and Their Combination in Patients With Type 2 Diabetes and Chronic Kidney Disease: Observations From a Prespecified Pilot Study of a Randomized Crossover Trial.
Apperloo EM, Heerspink HJL, van der Aart AB, Rouw D, van Raalte DH, Hoogenberg K, Jongs N, Muskiet MHA. Apperloo EM, et al. Among authors: heerspink hjl. Diabetes Care. 2025 Jan 10:dc242244. doi: 10.2337/dc24-2244. Online ahead of print. Diabetes Care. 2025. PMID: 39792380 No abstract available.
Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.
Apperloo EM, Tuttle KR, Pavo I, Haupt A, Taylor R, Wiese RJ, Hemmingway A, Cherney DZI, Sattar N, Heerspink HJL. Apperloo EM, et al. Among authors: heerspink hjl. Diabetes Care. 2025 Jan 2:dc241773. doi: 10.2337/dc24-1773. Online ahead of print. Diabetes Care. 2025. PMID: 39746157
The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol.
Kotwal SS, Perkovic V, Jardine MJ, Kim D, Shah NA, Lin E, Coggan S, Billot L, Vart P, Wheeler DC, de Boer IH, Zhang H, Hou FF, Sugawara Y, Marion J, Lewis RJ, Berry LR, McGlothlin A, Jha V, De Nicola L, Gorriz JL, Heerspink HJL; GKPTN and CAPTIVATE Investigators. Kotwal SS, et al. Among authors: heerspink hjl. JAMA Netw Open. 2024 Dec 2;7(12):e2449998. doi: 10.1001/jamanetworkopen.2024.49998. JAMA Netw Open. 2024. PMID: 39661388 Free PMC article.
Sex differences in the efficacy of angiotensin receptor blockers on kidney and cardiovascular outcomes among individuals with type 2 diabetes and diabetic kidney disease: post hoc analyses of the RENAAL and IDNT trials.
de Vries ST, Pena MJ, Tye SC, Peters SAE, van Raalte DH, Arnott C, Voors AA, Mol PGM, Denig P, Heerspink HJL. de Vries ST, et al. Among authors: heerspink hjl. Diabetologia. 2024 Dec 10. doi: 10.1007/s00125-024-06325-y. Online ahead of print. Diabetologia. 2024. PMID: 39656268
Endothelin receptor antagonists in chronic kidney disease.
Smeijer JD, Kohan DE, Dhaun N, Noronha IL, Liew A, Heerspink HJL. Smeijer JD, et al. Among authors: heerspink hjl. Nat Rev Nephrol. 2024 Dec 6. doi: 10.1038/s41581-024-00908-z. Online ahead of print. Nat Rev Nephrol. 2024. PMID: 39643698 Review.
474 results